TABLE 3

Inhibition of [3H]NBMPR binding

Cells were treated with MTS reagents and assessed for [3H]NBMPR binding in the presence and absence of a range of concentrations of test inhibitor as described for Fig. 3C. Each value is the mean ± S.E.M. from at least four independent experiments.

Cell Line and InhibitorKi
Control+MMTS
nM
hENT1
    Dipyridamole22 ± 830 ± 9
    Draflazine3.3 ± 0.72.8 ± 0.9
    Dilazep1.9 ± 0.41.2 ± 0.6
C87S
    Dipyridamole71 ± 26*N.D.
    Draflazine4.6 ± 2.1N.D.
    Dilazep4.5 ± 2.4N.D.
C193S
    Dipyridamole32 ± 10111 ± 32
    Draflazine3.5 ± 0.95.9 ± 1.2
    Dilazep5.2 ± 1.1*9.8 ± 4.2
C213S
    Dipyridamole22 ± 733 ± 11
    Draflazine2.2 ± 0.92.2 ± 0.8
    Dilazep2.6 ± 0.93.0 ± 1.3
C222S
    Dipyridamole32 ± 245 ± 14
    Draflazine3.2 ± 0.53.0 ± 0.7
    Dilazep3.2 ± 1.42.6 ± 0.8
  • N.D., not determined.

  • * P < 0.05, significantly different from the Ki determined in wild-type hENT1 (Student's t test for paired samples).

  • P < 0.05, significantly different from control (Student's t test for paired samples).